Europe Viscosupplementation Market, By Type (Single Injection, Cycle Three Injection Cycle, Five Injection Cycle), By End User (Hospitals, ASCs, Clinics), By Country (Western Europe (Germany, UK, France, Italy, Spain, Nordic Countries, Rest of Western Eur

Europe Viscosupplementation Market, By Type (Single Injection, Cycle Three Injection Cycle, Five Injection Cycle), By End User (Hospitals, ASCs, Clinics), By Country (Western Europe (Germany, UK, France, Italy, Spain, Nordic Countries, Rest of Western Europe), Eastern Europe (Russia, Rest of Eastern Europe)) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Viscosupplementation is a minimally invasive procedure that involves injection of the hyaluronic acid injected into a knee joint to promote better joint development and lubrication. It also helps in reducing pain, irritation and helps in improving osteoarthritis condition. Hyaluronic acid (HA) or hyaluronate is a non-sulfated glycosaminoglycan that is distributed throughout the body in epithelial, connective tissues, and neural tissues. Increasing prevalence of osteoarthritis in people is expected to boost demand for the viscosupplementation products.
Restraints of the Europe Viscosupplementation Market
Major factors hampering the growth of the viscosupplementation market during the forecast period constitutes of high costs and side effect.
Key features of the study:
This report provides in-depth analysis of the Europe viscosupplementation market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the Europe viscosupplementation market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Sanofi S.A., Anika Therapeutics, Inc., Seikagaku, Zimmer Biomet Holdings Inc., Meda AB (Mylan), Fidia Farmaceutici S.p.A., Bioventus LLC, Ferring B.V, Lifecore Biomedical, and LG Life Sciences.
Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
The Europe viscosupplementation market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.
Detailed Segmentation
Europe Viscosupplementation Market, By Type:
Single Injection Cycle
Three Injection Cycle
Five Injection Cycle
Europe Viscosupplementation Market, By End User:
Hospitals
ASCs
Clinics
Europe Viscosupplementation Market, By Country:
Western Europe
Germany
UK
France
Italy
Spain
Nordic Countries
Rest of Western Europe
Eastern Europe
Russia
Rest of Eastern Europe
Company Profiles
Sanofi S.A.*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Anika Therapeutics, Inc.
Seikagaku Corporation
Zimmer Biomet Holdings Inc.
Meda AB (Mylan)
Fidia Farmaceutici S.p.A.
Bioventus LLC
Ferring B.V
Lifecore Biomedical
LG Life Sciences
“*” marked represents similar segmentation in other categories in the respective section.